Elias D, Sideris L, Pocard M, Edè C, Ben Hassouna D, Ducreux M, Boige V, Côté J F, Lasser P
Department of Surgical Oncology, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cedex, France.
Ann Oncol. 2004 May;15(5):781-5. doi: 10.1093/annonc/mdh186.
The complete resection of macroscopic colorectal peritoneal carcinomatosis (PC), followed by intraoperative intraperitoneal chemohyperthermia (IPCH) to treat residual microscopic disease, leads to cure in some patients. We report preliminary results on survival in a phase II study using oxaliplatin (LOHP).
Twenty-four patients with macroscopic colorectal PC underwent complete resection of the PC followed by IPCH with LOHP performed in an open abdominal cavity. The dose of LOHP was 460 mg/m(2) in 2 l/m(2), during 30 min at 43 degrees C, at a flow rate of 2 l/min. During the hour preceding IPCH, they received an intravenous administration of 5-fluorouracil (400 mg/m(2)) and leucovorin (20 mg/m(2)).
Mean peritoneal tumoral extension (Sugarbaker's Index) was 16.9 +/- 9.5, median operative duration was 490 min and median blood loss was 965 ml. There were two postoperative deaths (8%) by intracerebral hemorrhage, and morbidity rate was 41.6%. Minimal follow-up was 18 months and median follow-up was 27.4 months (range 18.3-49.6). At 1, 2 and 3 years, overall survival rates were 83%, 74% and 65%, and disease-free survival rates were 70%, 50% and 50%, respectively. Only 32% of the 22 postoperative living patients presented a peritoneal recurrence. A peritoneal index >24 influenced survival, with a 17% recurrence rate at 2 years versus 63% when it was <24 (P = 0.005).
This new modality of treatment, when feasible, gives encouraging preliminary results, with a promising 3-year survival rate of 65%.
对肉眼可见的结直肠腹膜癌转移(PC)进行完整切除,随后进行术中腹腔内热化疗(IPCH)以治疗残留的微小病灶,可使部分患者治愈。我们报告了一项使用奥沙利铂(LOHP)的II期研究的生存初步结果。
24例肉眼可见结直肠PC患者接受了PC的完整切除,随后在开放腹腔中进行了含LOHP的IPCH。LOHP剂量为460mg/m²,溶于2l/m²的溶液中,在43℃下持续30分钟,流速为2l/分钟。在IPCH前1小时,他们接受了静脉注射5-氟尿嘧啶(400mg/m²)和亚叶酸钙(20mg/m²)。
平均腹膜肿瘤扩展(Sugarbaker指数)为16.9±9.5,中位手术时间为490分钟,中位失血量为965ml。有2例(8%)患者术后因脑出血死亡,发病率为41.6%。最短随访时间为18个月,中位随访时间为27.4个月(范围18.3 - 49.6个月)。1年、2年和3年时,总生存率分别为83%、74%和65%,无病生存率分别为70%、50%和50%。22例术后存活患者中只有32%出现腹膜复发。腹膜指数>24影响生存,2年时复发率为17%,而<24时为63%(P = 0.005)。
这种新的治疗方式在可行时能给出令人鼓舞的初步结果,3年生存率有望达到65%。